(Q37761270)

22 August 2017

1 reference

title

COX-2 as a target for cancer chemotherapy (English)

1 reference

22 August 2017

1 reference

Nilanjan Ghosh

1

1 reference

22 August 2017

Rituparna Chaki

series ordinal

2

1 reference

22 August 2017

Vivekananda Mandal

series ordinal

3

1 reference

22 August 2017

Subhash C Mandal

series ordinal

4

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

published in

Pharmacological Reports

1 reference

22 August 2017

volume

62

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

233-244

1 reference

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

High expression of cyclooxygenase-2 in macrophages of human colonic adenoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclooxygenase-2: a novel target for cancer chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Inflammatory response: pathway across the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Prostaglandin H synthase and xenobiotic oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Human cyclooxygenase-2 cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Tumour-educated macrophages promote tumour progression and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclooxygenases: structural, cellular, and molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Why there are two cyclooxygenase isozymes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Carcinogen substrate specificity of human COX-1 and COX-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Host cyclooxygenase-2 modulates carcinoma growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

Dihydroxy Bile Acids Activate the Transcription of Cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2810%2970262-0

7 January 2021

10.1016/S1734-1140(10)70262-0

Identifiers

DOI

1 reference

22 August 2017

1 reference